{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:17:50Z","timestamp":1777529870680,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.mcna.2020.09.014","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T10:17:54Z","timestamp":1610619474000},"page":"311-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica"],"prefix":"10.1016","volume":"105","author":[{"given":"Sarah","family":"El Chami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mcna.2020.09.014_bib1","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2020.09.014_bib2","first-page":"57","article-title":"The different clinical patterns of giant cell arteritis","volume":"37","author":"de Boysson","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.014_bib3","doi-asserted-by":"crossref","first-page":"e2368","DOI":"10.1097\/MD.0000000000002368","article-title":"Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis","volume":"95","author":"Hernandez-Rodriguez","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.014_bib4","first-page":"278","article-title":"Spectrum of aging changes in temporal arteries. Its significance, in interpretation of biopsy of temporal artery","volume":"90","author":"Lie","year":"1970","journal-title":"Arch Pathol"},{"key":"10.1016\/j.mcna.2020.09.014_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amsu.2017.06.020","article-title":"Temporal artery biopsy in the diagnosis of giant cell arteritis: Does the end justify the means?","volume":"20","author":"Bowling","year":"2017","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.014_bib6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard.2005.042770","article-title":"Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?","volume":"65","author":"Mahr","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.014_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcjo.2013.12.008","article-title":"Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis","volume":"49","author":"Durling","year":"2014","journal-title":"Can J Ophthalmol"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.014_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7326\/0003-4819-120-12-199406150-00003","article-title":"How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?","volume":"120","author":"Achkar","year":"1994","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.014_bib9","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3174\/ajnr.A0638","article-title":"Diagnostic value of high-resolution MR imaging in giant cell arteritis","volume":"28","author":"Bley","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3 Suppl 49","key":"10.1016\/j.mcna.2020.09.014_bib10","first-page":"S76","article-title":"1T magnetic resonance imaging in the diagnosis of giant cell arteritis: comparison with ultrasonography and physical examination of temporal arteries","volume":"26","author":"Ghinoi","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.014_bib11","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1002\/art.21226","article-title":"Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging","volume":"52","author":"Bley","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.014_bib12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1148\/radiol.14140056","article-title":"Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial","volume":"273","author":"Klink","year":"2014","journal-title":"Radiology"},{"issue":"90","key":"10.1016\/j.mcna.2020.09.014_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20900","article-title":"The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study","volume":"20","author":"Luqmani","year":"2016","journal-title":"Health Technol Assess"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.014_bib14","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/art.23699","article-title":"Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis","volume":"58","author":"Bley","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.014_bib15","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/art.11480","article-title":"Mortality of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.014_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3899\/jrheum.110652","article-title":"Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis","volume":"39","author":"Grayson","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.014_bib17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.lpm.2019.07.032","article-title":"[The additional value of imaging (excluding Doppler) for the diagnosis and follow-up of giant cell arteritis]","volume":"48","author":"de Boysson","year":"2019","journal-title":"Presse Med"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.014_bib18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s10067-017-3669-7","article-title":"The value of ultrasound in diagnosing extracranial large-vessel vasculitis compared to FDG-PET\/CT: A retrospective study","volume":"36","author":"Loffler","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.014_bib19","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/rheumatology\/kes153","article-title":"Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis","volume":"51","author":"Hauenstein","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.014_bib20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.semarthrit.2011.10.005","article-title":"Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis","volume":"41","author":"Kermani","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.014_bib21","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.014_bib22","first-page":"1484","article-title":"A\u00a0randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.014_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018\u00a0Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.014_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","article-title":"British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis","volume":"59","author":"Mackie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.014_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.42.4.374","article-title":"Polymyalgia rheumatica and corticosteroids: how much for how long?","volume":"42","author":"Behn","year":"1983","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.014_bib26","first-page":"171","article-title":"Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis","volume":"19","author":"Hachulla","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.014_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","article-title":"Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study","volume":"82","author":"Hunder","year":"1975","journal-title":"Ann Intern Med"},{"issue":"10031","key":"10.1016\/j.mcna.2020.09.014_bib28","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.014_bib29","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.014_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.014_bib31","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.mcna.2020.09.014_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/annrheumdis-2019-eular.2099","article-title":"Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of the Giacta Trial","volume":"78","author":"Stone","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.014_bib33","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.014_bib34","first-page":"495","article-title":"A\u00a0prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.014_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.014_bib36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.014_bib37","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.014_bib38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","article-title":"Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis","volume":"48","author":"Salvarani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.014_bib39","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.014_bib40","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.semarthrit.2006.10.001","article-title":"Statin therapy does not seem to benefit giant cell arteritis","volume":"36","author":"Narvaez","year":"2007","journal-title":"Semin Arthritis Rheum"},{"issue":"9634","key":"10.1016\/j.mcna.2020.09.014_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.014_bib42","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends Over 45 Years: A Population-Based Study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.014_bib43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: a 10-year epidemiologic and clinical study","volume":"97","author":"Chuang","year":"1982","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.014_bib44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.014_bib45","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.014_bib46","first-page":"1550","article-title":"The use of methotrexate in polymyalgia rheumatica","volume":"23","author":"Feinberg","year":"1996","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.014_bib47","first-page":"395","article-title":"Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids","volume":"26","author":"Cimmino","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.014_bib48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.014_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2013.01.003","article-title":"Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature","volume":"43","author":"Macchioni","year":"2013","journal-title":"Semin Arthritis Rheum"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712520301267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712520301267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:45:00Z","timestamp":1758419100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712520301267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0025712520301267"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.014","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}